Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulation

27 Jun 2025

Abstract excerpt

Histone deacetylase inhibitors (HDAC inhibitors, HDACi) have garnered considerable attention due to their potential in treating various types of malignant tumors. Histone deacetylases (HDACs) not only influence chromatin structure and gene transcription by regulating histone acetylation status but also acetylate various non-histone proteins. They are widely involved in several key biological processes, such as...

Topics

Join the communities discussing this publication.

Histone Deacetylase Inhibitors Research
Peptidase Inhibition and Analysis
Protein Degradation and Inhibitors

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40657246
DOI: 10.3389/fonc.2025.1576781

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulationPMID 40657246Read ↗

HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory DiseasesSemantic proximity Read ↗

Histone Deacetylase Inhibitors as Immunomodulators in Cancer TherapeuticsSemantic proximity Read ↗

Targeting histone deacetylases for the treatment of cancer and inflammatory diseasesSemantic proximity Read ↗

HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseasesSemantic proximity Read ↗

Mechanisms of HDACs in cancer developmentSemantic proximity Read ↗

Histone-Deacetylase Inhibitors for the Treatment of CancerSemantic proximity Read ↗

HDAC inhibitors and immunotherapy; a double edged sword?Semantic proximity Read ↗

Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in CancerSemantic proximity Read ↗

Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human DiseasesSemantic proximity Read ↗

Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer ImmunotherapySemantic proximity Read ↗

Targeting Histone Deacetylases: Opportunities for Cancer Treatment and ChemopreventionSemantic proximity Read ↗

Role of histone deacetylase inhibitors in non-neoplastic diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.